Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B

Natera, Inc.

2022-FY EPS reported -$5.57 revenue$820,222,000

Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).
Full-year 2022 revenue $820.2M (+31.1% YoY); net loss $547.8M ($5.57/diluted) vs $471.7M ($5.21) in 2021.
Oncology tests 196,000 in 2022 (+158% YoY); 40 peer-reviewed studies for Signatera published.
2023 guidance: revenue $980M-$1B; gross margin 41%-44%; net cash consumption $300M-$325M.
Appointed Ruth Williams-Brinkley to board effective March 2, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.